167 related articles for article (PubMed ID: 21739328)
1. The psychometric validation of a 1-week recall period for the OAB-q.
Coyne KS; Gelhorn H; Thompson C; Kopp ZS; Guan Z
Int Urogynecol J; 2011 Dec; 22(12):1555-63. PubMed ID: 21739328
[TBL] [Abstract][Full Text] [Related]
2. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
[TBL] [Abstract][Full Text] [Related]
3. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
4. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
8. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
9. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder.
Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N
Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200
[TBL] [Abstract][Full Text] [Related]
10. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
11. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
[TBL] [Abstract][Full Text] [Related]
13. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
Herschorn S; Heesakkers J; Castro-Diaz D; Wang JT; Brodsky M; Guan Z;
Curr Med Res Opin; 2008 Dec; 24(12):3513-21. PubMed ID: 19032133
[TBL] [Abstract][Full Text] [Related]
14. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
[TBL] [Abstract][Full Text] [Related]
15. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
[TBL] [Abstract][Full Text] [Related]
16. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
[TBL] [Abstract][Full Text] [Related]
17. The responsiveness of the Overactive Bladder Questionnaire (OAB-q).
Coyne KS; Matza LS; Thompson CL
Qual Life Res; 2005 Apr; 14(3):849-55. PubMed ID: 16022077
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
19. The responsiveness of the OAB-q among OAB patient subgroups.
Coyne KS; Matza LS; Thompson C; Jumadilova Z; Bavendam T
Neurourol Urodyn; 2007; 26(2):196-203. PubMed ID: 17016794
[TBL] [Abstract][Full Text] [Related]
20. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]